Measures of blood vessel health derived from routine blood pressure

Ez-PAVE trial: aiming for LDL-C below 55 mg/dL rather than

CHAMPION-AF trial: Left atrial appendage closure proves non-inferior to NOACs

VESALIUS-CV subanalysis: evolocumab reduces major adverse cardiac events by 31%

Phase 2 trial of tonlamarsen in resistant hypertension: the drug’s

STEMI-DTU trial: Delayed reperfusion with LV unloading shows no significant